@article{TAU26019,
author = {Su-Min Lee},
title = {Prognosis in high-grade T1 bladder cancer: host immune response and tumour infiltrating lymphocytes},
journal = {Translational Andrology and Urology},
volume = {8},
number = {Suppl 3},
year = {2019},
keywords = {},
abstract = {Bladder cancer is a heterogeneous disease that poses a challenge to the treating clinician. In non-muscle-invasive bladder cancer (NMIBC), the EORTC risk tables have helped stratify patients into low, intermediate and high-risk groups, but are now over a decade old (1). Within the high-risk group lies high-grade T1 (HGT1) disease, a variable group of patients with tumors that can behave similarly to muscle-invasive bladder cancer. Rates of progression to muscle-invasive disease and metastases vary between 25% and 73%, and long-term follow-up suggests up to 25% of patients may die from bladder cancer (2). Management of these patients can vary from immunotherapy to radical cystectomy, and a current unmet research need lies in stratifying patients who would most benefit from radical treatment.},
issn = {2223-4691}, url = {https://tau.amegroups.org/article/view/26019}
}